cagrilintide novo nordisk shares slide despite promising weight loss trial results Novo Nordisk's next-generation weight-loss drug
Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Novo Nordisk Offers New Contender in Weight Management Novo Nordisk to explore CagriSema weight loss potential in new trial Reuters Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly Reuters
Pay in 4 interest-free payments of $5.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16



